Indium (111In) altumomab pentetate: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 53: | Line 53: | ||
{{antineoplastic-drug-stub}} | {{antineoplastic-drug-stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Revision as of 01:52, 11 February 2025
| Indium (111In) altumomab pentetate | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 156586-92-4 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Indium (111In) altumomab pentetate (INN) (USP, indium In 111 altumomab pentetate; trade name Hybri-ceaker) is a mouse monoclonal antibody linked to pentetate which acts as a chelating agent for the radioisotope indium-111. The drug is used for the diagnosis of colorectal cancer.<ref>WHO Drug Information</ref><ref>FDA</ref>
References
<references group="" responsive="1"></references>
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
